PURPOSE Total body irradiation (TBI) before allogeneic hematopoietic stem cell
transplantation (HSCT) in pediatric patients with acute lymphoblastic leukemia (ALL) is …

ABSTRACT Introduction: Busulfan (Bu) is an alkylating agent with a limited therapeutic
margin and exhibits inter-patient variability in pharmacokinetics (PK). Despite decades of …

The inter-individual differences in cancer susceptibility are somehow correlated with the
genetic differences that are caused by the polymorphisms. These genetic variations in drug …

Cytotoxic drugs are highly efficacious and also have low therapeutic index. A great degree
of caution needs to be exercised in their usage. To optimize the efficacy these drugs need to …

We aimed to review the pharmacokinetics (PK) of intravenous busulfan in paediatric
patients, identify covariate factors influencing exposure, investigate evidence of changes in …

Intravenous busulfan is widely used as part of myeloablative conditioning regimens in
children and young adults undergoing allogeneic hematopoietic cell transplantation (HCT) …

Busulfan (Bu) is a common component of conditioning regimens before hematopoietic stem
cell transplantation (HSCT) and is known for high interpatient pharmacokinetic (PK) …

The advent of novel immunotherapies, such as blinatumomab, inotuzumab, and chimeric
antigen receptor (CAR) T cell therapy, has revolutionized the therapeutic landscape in the …

Background Intravenous (IV) busulfan (Bu) dosing approved in Europe based on 5 body
weight (BW) strata has been validated for targeting Bu exposures in children undergoing …

Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better
outcome of hematopoietic stem cell transplantation (HSCT). Further improvement could be …